Earendil Labs closed a $787 million financing to scale an AI‑driven biologics discovery engine and advance a broad pipeline of antibody, bispecific and ADC candidates across autoimmune disease and oncology. Investors include Dimension, Luminous Ventures and Sanofi, and the company plans to push multiple programs toward clinical testing while building expanded R&D infrastructure in the U.S. and China. Earendil says its platform has generated more than 40 programs and listed several candidates at various preclinical stages; one program targeting IBD is ready for Phase 2. The funding positions Earendil to operate at “a fundamentally different scale,” enabling concurrent IND‑enabling work and potential public listings or partnerships in Asia and Hong Kong.